Sagespring Wealth Partners LLC Makes New Investment in Amedisys, Inc. (NASDAQ:AMED)

Sagespring Wealth Partners LLC acquired a new stake in shares of Amedisys, Inc. (NASDAQ:AMED) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 2,883 shares of the health services provider’s stock, valued at approximately $262,000.

A number of other hedge funds also recently made changes to their positions in the stock. Blue Trust Inc. lifted its holdings in Amedisys by 55.1% during the fourth quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after purchasing an additional 124 shares in the last quarter. HBW Advisory Services LLC purchased a new position in shares of Amedisys during the 4th quarter valued at $38,000. Versant Capital Management Inc boosted its holdings in Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after buying an additional 183 shares during the period. Vestcor Inc purchased a new stake in Amedisys in the 4th quarter worth $73,000. Finally, Venturi Wealth Management LLC raised its holdings in Amedisys by 397.4% during the fourth quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after acquiring an additional 779 shares during the period. 94.36% of the stock is currently owned by institutional investors.

Amedisys Price Performance

Shares of Amedisys stock opened at $91.91 on Thursday. The firm has a market cap of $3.02 billion, a PE ratio of 36.47, a PEG ratio of 1.78 and a beta of 0.89. The stock has a 50 day moving average of $92.16 and a 200 day moving average of $91.98. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95.

Amedisys (NASDAQ:AMED) last posted its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The business had revenue of $598.05 million during the quarter, compared to analysts’ expectations of $602.38 million. On average, research analysts expect that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

AMED has been the subject of several research analyst reports. Stephens reiterated an “equal weight” rating and set a $101.00 target price on shares of Amedisys in a research report on Tuesday, March 4th. Royal Bank of Canada restated an “outperform” rating and issued a $100.00 price target on shares of Amedisys in a research note on Wednesday. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $100.75.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.